Serina Therapeutics enrolls first patient in Parkinson’s trial
Serina Therapeutics has dosed the first patient in a Phase 1b registrational trial of SER-252 for advanced Parkinson's disease; the study will assess safety, tolerability, pharmacokinetics and preliminary efficacy in patients with motor fluctuations and follows regulatory clearance to begin enrollment. SER-252 uses Serina's polymer-based delivery to provide sustained subcutaneous apomorphine exposure intended to extend therapeutic windows and reduce motor complications, forming a lead program in the company's neurological disorder portfolio and a key step toward future regulatory submissions.
Why it mattersPhase 1b enrollment of SER-252 for advanced Parkinson's disease indicates imminent safety data, prompting investors to reassess timelines.